Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Autor: Constantin, Arnaud, Gottenberg, Jacques Eric, Loiseau-Peres, Sylvie, Nguyen, Minh, Schaeverbeke, Thierry, Alten, Rieke H.-E., Amberger, Christopher, Biewer, Werner A., Boche, Konrad, Burmester, Gerd Ruediger, Engel, Andreas, Feuchtenberger, Martin, Fleck, Martin, Gauler, Georg, Heilig, Bernhard, Höhle, Maria, Iking-Konert, Christof, Kästner, Peter, Kofler, David, Krueger, Klaus, Kühne, Cornelia, Kurthen, Reiner, Schulze-Koops, Hendrik, Schwenke, Holger, Sieburg, Maren, Specker, Christof, Tony, Hans-Peter, Wassenberg, Siegfried, Wendler, Jörg, Caporali, Roberto, Epis, Oscar, Matucci-Cerinic, Marco, Salvarani, Carlo, Dubikov, Alexander, Kamalova, Rimma, Korolev, Maxim, I. Mazurov, Vadim, Puntus, Ekaterina, Damjanov, Nemanja, Ilic, Tatjana, Lazarevic, Milijanka, Milenkovic, Sasa, Petronijevic, Milan, Gabay, Cem, Bouajina, Elyes, Elleuch, Mohamed, Burmester, Gerd R ^*, Buttgereit, Frank, Bernasconi, Corrado, Álvaro-Gracia, Jose M, Castro, Nidia, Dougados, Maxime, van Laar, Jacob M, Nebesky, Jan Michael, Pethoe-Schramm, Attila, Donath, Marc Y, John, Markus R

Publikováno v: In The Lancet 25-31 July 2020 396(10246):267-276

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Autor: Ahmed, Khalid, Alper, Jeffrey, Barkham, Nichol, Bennett, Ralph E., García, Francisco Javier Blanco, Alonso, Ricardo Blanco, Blumstein, Howard B., Brooks, Michael S., Burmester, Gerd-Rüdiger, Cagnoli, Patricia, Caldron, Paul H., Cantagrel, Alain, Chen, Der-Yuan, Churchill, Melvin A., Jr, Codding, Christine E., Combe, Benard, Deane, Peter M.G., Del Giudice, Jose, Deodhar, Atul A., Dhar, Rajat K., Dokoupilova, Eva, Egan, Rita M., Everding, Andrea, Galíndez, Eva, Genovese, Mark, Goddard, David H., Gottlieb, Alice, Goupille, Philippe, Griffin, Robert M., Gupta, Ramesh C., Hall, Stephen, Hatti, Kalpita, Howell, Mary P., Huang, Yu-Huei, Jajoo, Ramina, Janssen, Namieta M., Kiltz, Uta, Kivitz, Alan J., Klein, Steven J., Korkosz, Mariusz P., Kotha, Roshan, Kremer, Joel M., Lue, Cummins, de la Fuente, José Luis Marenco, Marzo-Ortega, Helena, Masmitja, Jordi Gratacós, Mease, Philip J., Meroni, Pier Luigi, Mueller, Eric C., Nandagudi, Anupama C., Nash, Peter, Fernández-Nebro, Antonio, Neuwelt, Clark M., Orbai, Ana Maria, Oza, Meera R., Parks, Deborah L., Pattanaik, Debendra, Rell-Bakalarska, Maria E., Rosmarin, David, Roussou, Euthalia, Rychlewska-Hanczewksa, Anna I., Sikes, David H., Stack, Michael T., Sunkureddi, Prashanth, Tahir, Hasan, Thaçi, Diamant, Tsai, Tsen-Fang, Turkiewicz, Anthony M., Unger, Leonore, Cabello, Raúl Veiga, Wagner, Ulf, Wei, Cheng-Chung, Wells, Alvin F., Youssef, Peter, Zielinska, Agnieszka, Kirkham, Bruce, Okada, Masato, Rahman, Proton, Burmester, Gerd-Ruediger, Adams, David H, Kerr, Lisa, Lee, Chin, Shuler, Catherine L

Publikováno v: In The Lancet 10-16 June 2017 389(10086):2317-2327

Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial

Autor: Humrich, Jens Y ^*, von Spee-Mayer, Caroline, Siegert, Elise, Bertolo, Martina, Rose, Angelika, Abdirama, Dimas, Enghard, Philipp, Stuhlmüller, Bruno, Sawitzki, Birgit, Huscher, Dörte, Hiepe, Falk, Alexander, Tobias, Feist, Eugen, Radbruch, Andreas, Burmester, Gerd-Rüdiger, Riemekasten, Gabriela

Publikováno v: In The Lancet Rheumatology September 2019 1(1):e44-e54